# Atea Pharmaceuticals, Inc. (AVIR)

> Source: Nexqual · https://nexqual.com/AVIR · data as of 2026-10-15 20:00 UTC · cite as "Nexqual, Atea Pharmaceuticals, Inc. (AVIR), nexqual.com/AVIR" · informational, not investment advice.

**Price:** USD 4.53 (-2.16% on the day) · last close of Oct 15, 2026; US market closed, not a live price. Prev close 4.63 · day 4.48–4.78 · 52w 2.87–6.45 · market cap $363M · NMS

## Key facts
- Analysts: Buy (mean 2.33 on a 1–5 scale) (3 analysts), mean target USD 9.42 (range 7–11.25).
- Total return with dividends: 1Y +45.2% vs S&P 500 +18.1%; 5Y -88.5% vs S&P 500 +85.1%.
- Next earnings: 2026-11-11, EPS estimate USD -0.51, revenue estimate $0K.

## Analysts
Consensus Buy (mean 2.33 on a 1–5 scale), 3 analysts; mean target USD 9.42 (low 7, high 11.25).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-13 | Morgan Stanley | Target raised | Equal-Weight | $6 → $7 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-16) | 5Y (from 2021-10-11) |
|---|---|---|
| Total return | +45.2% | -88.5% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | +45.4% | -35.0% |
| Volatility (annualized) | 51.1% | 73.8% |
| Max drawdown | -33.3% (Mar 2026→May 2026) | -93.1% (Oct 2021→Apr 2025) |

## Peers (Biotechnology)
RYTM (Rhythm Pharmaceuticals, Inc.) USD 87.97 +1.57% · BLTE (Belite Bio, Inc) USD 152.62 +0.49% · IOVA (Iovance Biotherapeutics, Inc.) USD 14.72 +1.52% · PRAX (Praxis Precision Medicines, Inc) USD 248.24 +2.01% · IONS (Ionis Pharmaceuticals, Inc.) USD 44.12 +4.11% · SYRE (Spyre Therapeutics, Inc.) USD 80.1 -0.44%

## More
Full page: https://nexqual.com/AVIR · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt